Carmat: Edison Open House Healthcare 2022

Carmat: Edison Open House Healthcare 2022

Associated equity: Carmat

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. Management is taking corrective actions with recent quality challenges.

Carmat — 4 videos in collection

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. It received a CE mark in the EU and Carmat is conducting an early feasibility study in the United States.

• Tell us about Carmat’s history and vision.
• Please explain how physiological heart replacement therapy differs from other artificial hearts.
• How large do you anticipate the unmet need in the bridge-to-transplant market to be?
• Please explain what’s been happening for Carmat in 2021, including its first commercial implants.
• What are the next steps in terms of commercial implant trials in Europe and the United States?
• When do you expect to receive approvals, particularly in the US market?
• Which milestones should investors focus on in the coming year?


You may also be interested in these:

Healthcare

Carmat - Edison Open House interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free